A literature digest
Ipamorelin releases growth hormone cleanly — and the body-composition question is what the research keeps circling back to.
What the studies measured in lean mass, fat, bone, and recovery — and where the human data still runs out — read plainly and cited line by line.
The short version
Ipamorelin is a small lab-made peptide — a five-amino-acid chain — that tells the pituitary gland (the master gland at the base of the brain) to release a pulse of growth hormone. What makes it stand out is how clean that signal is: it raises growth hormone without meaningfully raising the stress hormone cortisol or the milk hormone prolactin, which older peptides in its family did [1]. Most of the interest, and most of the marketing, is about body composition — leaner mass, less fat, faster recovery. But the honest picture is narrower than the hype. The strongest data is in rats and a handful of human studies, and the only proper human trial — testing it for slow bowels after surgery — did not work [3]. It has never been approved as a medicine anywhere. This site summarizes what the published research found, in plain words, with every number tied to its source — and what people report, including the downsides, is on the effects page.
What the ipamorelin literature has actually established
Ipamorelin is a synthetic pentapeptide — sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — that selectively activates the ghrelin receptor (GHS-R1a, the cell-surface switch the natural hunger hormone ghrelin flips) on the pituitary's growth-hormone cells, triggering a short, discrete pulse of growth hormone (GH) [1]. Its defining property is selectivity. In the 1998 study that introduced it, ipamorelin released GH potently in rat pituitary cells, anaesthetised rats, and conscious pigs (pig ED50 = 2.3 nmol/kg, comparable to the older peptide GHRP-6 at 3.9 nmol/kg), yet did not raise cortisol or ACTH even at doses more than 200 times its GH-releasing dose [1]. That clean profile is the whole reason it is studied separately from its messier predecessors.
The body-composition story flows downstream of that pulse. In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 µg/day raised the rate of long-bone growth from 42 µm/day on vehicle to 44, 50, and 52 µm/day — a clear dose-response — with no measurable change in circulating IGF-1 or bone-turnover markers [4]. That detail matters: the skeletal effect appeared to be driven by the local GH pulse rather than a sustained rise in IGF-1, which is the systemic growth factor most GH effects run through.
The most recent in-vivo work points the same direction. In a 2024 ferret study, ipamorelin (1–3 mg/kg) cut chemotherapy-driven body-weight loss by roughly 24% during the delayed phase, though it had no anti-nausea effect [5]. The signal across these studies is a compound that defends and reshapes body mass through a clean GH pulse — promising in animals, and still mostly animals.
The body-composition lens, and its limits
Read in sequence, the Ipamorelin research tells a consistent preclinical story: a GH pulse that builds bone, defends body weight under metabolic stress, and — per the reports people share — tracks with recovery and a gradual leaner look over weeks. The mechanism is coherent and the animal effect sizes are real.
The limit is human evidence. There is no controlled human trial showing ipamorelin changes body composition. The only published Phase 2 trial used it for postoperative ileus — sluggish bowels after surgery — and missed its primary endpoint outright [3]. Its human pharmacokinetics were mapped once, in eight volunteers per dose [2]. Everything else marketed as fat loss or muscle gain rests on mechanism and short rodent studies, not human outcomes. That gap is the most important fact on this site, and we keep it in view on every page.
How to read this site
Every quantitative claim here — every dose, half-life, percentage, and species — is tied to a numbered citation you can check on the Ipamorelin references page. The Ipamorelin effects page collects what the research-use community reports, clearly labelled as anecdotal, alongside cited safety cautions. The research page walks the mechanism and the key studies; the dosage page describes what was administered to which species at which dose, never a human protocol. Two dedicated pages take on the questions readers actually search: whether ipamorelin causes weight gain, and what benefits the research supports.
Ipamorelin is not FDA-approved. It is the subject of a real, if thin, research literature — and that literature, read honestly, is what this page documents.